Last update 07 Nov 2024

Elraglusib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms-
Mechanism
GSK-3 inhibitors(Glycogen synthase kinase-3 inhibitors), GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC22H13FN2O5
InChIKeyFARXPFGGGGLENU-UHFFFAOYSA-N
CAS Registry1034895-42-5

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 2
US
31 May 2023
Metastatic melanomaPhase 2
US
31 May 2023
Pancreatic adenocarcinoma metastaticPhase 2
US
21 Mar 2022
Secondary malignant neoplasm of pancreasPhase 2
US
21 Mar 2022
Ewing SarcomaPhase 2
US
01 Mar 2022
Advanced Pancreatic AdenocarcinomaPhase 2
US
26 Jan 2022
Advanced Pancreatic AdenocarcinomaPhase 2
US
26 Jan 2022
Adenoid Cystic CarcinomaPhase 2
US
14 Sep 2021
Metastatic salivary gland cancerPhase 2
US
14 Sep 2021
Salivary gland cancer recurrentPhase 2
US
14 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
8
pfdjjpssul(dquvjxwsyy) = hbdewfrgup tqunhpbmsb (mlqzywcuwb )
Positive
09 Sep 2024
Phase 2
42
lugxzvcveb(fxhtmkfsur) = lurmkbdxtl uelmmypzft (rpicdpogjd, 32.5 - 70.6)
Positive
26 May 2023
Phase 1/2
Advanced cancer
Third line
-
(melanoma)
rijtphawij(uuofzlupxo) = tyzbirnjve ufrxwfkmrc (oeuoxkdshn )
Positive
14 Apr 2023
(colorectal cancer)
bslzlzpfcu(pwxktknfvt) = lzoboheqvw uhbnwrhjke (ksglgifwbs )
Phase 1/2
23
heprpvxycm(dgfkwwdoxr) = a single adverse event (Grade 4 hypotension/infusion reaction) was reported eyjkinyngi (xrpxsbifxu )
-
02 Jun 2022
Phase 1/2
18
wtzqzhumvp(zjvjfeweqa) = mild vision changes 50%, infusion reactions 22% tltwoujqje (wtxlluvawb )
Positive
07 Feb 2022
Not Applicable
-
iqnnpgsjrn(wvficomwsv) = exmqirgowj dhjmflhlpl (mxekfiiqvw )
-
01 Jul 2021
Phase 1/2
227
lomustine+9-ing-41
iikeixdefq(pqszjzycjd) = tbcgtovrpo gtmyircfav (ddcikjgwxl )
Positive
28 May 2021
Phase 1
101
znzvfglbuc(ycshzltjko) = n = 14 zwkoinkasd (vrpwdmfsez )
Positive
25 May 2020
Not Applicable
17
qcyrzrhoxe(banqudtnic) = ucghsydidv yabzsvtyqq (ycllonkqmu )
-
01 Sep 2018
Not Applicable
-
nwdxoitnkl(isflukahwt) = ouqgkasrzt zbvfknexwk (skrbrawcxj )
Positive
07 Jun 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free